subscribeSubscribe
Alkermes Presents Analyses From Long-Term Safety Study of LYBALV at SIRS

Alkermes Presents Analyses From Long-Term Safety Study of LYBALV at SIRS
PR NEWSWIRE
08 Apr 2024
Share Share
Alkermes Announces Topline Results From Study of LYBALVI

Alkermes Announces Topline Results From Study of LYBALVI
PR NEWSWIRE
03 Jan 2024
Share Share
Alkermes` Lybalvi a new litmus test for mental illness marketing

Alkermes` Lybalvi a new litmus test for mental illness marketing
Ben Adams FIERCEPHARMA
24 Feb 2022
Share Share
Alkermes Shows Positive Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI

Alkermes Shows Positive Results From ENLIGHTEN-Early Phase 3b Study of LYBALVI
PRNEWSWIRE
08 Feb 2022
Share Share
Alkermes schizophrenia drug gets U.S. FDA approval

Alkermes schizophrenia drug gets U.S. FDA approval
REUTERS
02 Jun 2021
Share Share
FDA Accepts Alkermes` Resubmission of New Drug Application for ALKS 3831

FDA Accepts Alkermes` Resubmission of New Drug Application for ALKS 3831
PRNEWSWIRE
29 Dec 2020
Share Share
Journal of Clinical Psychiatry Publishes Data from Alkermes` Pha3 ALKS 3831

Journal of Clinical Psychiatry Publishes Data from Alkermes` Pha3 ALKS 3831
PR NEWSWIRE
04 Mar 2020
Share Share
Did a disaster crush your stock in 2018? These biotechs were happy with CEO

Did a disaster crush your stock in 2018? These biotechs were happy with CEO
John Carroll ENDPTS
03 May 2019
Share Share
FDA advisors turn down Alkermes’ ALKS 5461

FDA advisors turn down Alkermes’ ALKS 5461
Selina McKee PHARMA TIMES
03 Nov 2018
Share Share
Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for MDD

Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for MDD
PR NEWSWIRE
30 Oct 2018
Share Share